Table 1. Baseline characteristics of patients at enrollment in the ANRS PRIMO and COPANA cohort studies.
| Enrolled during primary HIV infection | Enrolled during chronic HIV infection | p-value | |
| N = 1267 | N = 800 | ||
| Year of enrollment | |||
| 1996–2003 | 488 | ||
| 2004–05 | 172 | 341 | |
| 2006–07 | 245 | 375 | |
| 2008–10 | 362 | 84 | |
| Transmission group, % (n) | <0.0001a | ||
| Heterosexual | 25.5 (323) | 43.8 (350) | |
| Homosexual/bisexual | 68.2 (864) | 43.5 (348) | |
| Other/multiple/unknown | 6.3 (80) | 12.8 (102) | |
| Women, % (n) | 15.9 (201) | 29.6 (237) | <0.0001a |
| Place of birth, % (n) | <0.0001a | ||
| France | 82.8 (1041) | 53.7 (421) | |
| Sub-Saharan Africa | 7.2 (91) | 34.8 (273) | |
| other | 10.0 (126) | 11.5 (90) | |
| Age, years | |||
| median (IQR) | 35.2 (29.3; 42.9) | 34.8 (29.8; 43.4) | 0.4b |
| CD4, cells/mm3 | |||
| median (IQR) | 519 (372; 679) | 383 (238; 545) | <0.0001b |
| categorized, %(n) | <0.0001a | ||
| <200/mm3 | 3.6 (45) | 19.5 (156) | |
| 200–350/mm3 | 16.8 (213) | 23.8 (190) | |
| 351–500/mm3 | 26.8 (339) | 26.4 (211) | |
| >500/mm3 | 52.9 (670) | 30.4 (243) | |
| HIV viral load | |||
| median (IQR) | 5.11 (4.47; 5.70) | 4.44 (3.81; 5.02) | <0.0001b |
| >5 log copies/mL, % (n) | 54.9 (695) | 25.4 (202) | <0.0001a |
| Stage C | 0.0 (0) | 7.8 (62) | <0.0001 |
| Hepatitis B | |||
| Ag HbS+ c | 2.0 (23) | 3.5 (27) | 0.03 |
| Hepatitis C | |||
| Anti-HCV antibody (+) d | 3.3 (39) | 4.4 (34) | 0.2 |
a
chi2 test.
b
Wilcoxon test.
c
among 1168 PRIMO patients and 763 COPANA patients with available data.
d
among 1192 PRIMO patients and 764 COPANA patients with available data.